The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical
Research Funding - MSD (Inst); Novartis (Inst)
Real-world data on treatment patterns and survival among ALK+ NSCLC patients in Japan.
 
Kaname Nosaki
No Relationships to Disclose
 
Ryo Toyozawa
Honoraria - AstraZeneca Japan; Lilly Japan; Nippon Kayaku
 
Kenichi Taguchi
Honoraria - AstraZeneca Japan; Lilly Japan; Nippon Kayaku
 
Makoto Edagawa
Honoraria - Ono Pharmaceutical
 
Shin-ichiro Shimamatsu
Honoraria - Ono Pharmaceutical
 
Goji Toyokawa
No Relationships to Disclose
 
Fumihiko Hirai
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Novartis (Inst)
 
Masafumi Yamaguchi
Honoraria - Astellas Pharma; AstraZeneca Japan; Johnson & Johnson; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yoko Takeda
No Relationships to Disclose
 
Takashi Seto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Kissei Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Mitsuhiro Takenoyama
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Yukito Ichinose
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Taiho Pharmaceutical; Taisho Toyama Pharma
Research Funding - Takeda (Inst)